IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years – Retail Calls It ‘Opportunity Of A Lifetime’
Ionis Pharmaceuticals’ Phase 3 trial, conducted in partnership with AstraZeneca, failed to meet its primary endpoint in patients with transthyretin-mediated amyloid cardiomyopathy.
Read the full articleYou might also wanna read
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drug
AstraZeneca Plunges After New Heart Disease Drug Fails Trial
AstraZeneca’s shares fell as much as 10.6% in London, which is its largest intraday plummet since 2017, per Bloomberg. The post AstraZeneca
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems
Dividenden-Garant Astrazeneca im freien Fall: Studien-Flop schockt Anleger
Nackenschlag für den britisch-schwedischen Pharma-Konzern Astrazeneca und den Entwicklungspartner Ionis Pharmaceuticals. Der Hoffnungsträger
AstraZeneca Stock Tumbles 6% Following Late-Stage Heart Disease Drug Trial Failure
AstraZeneca stock fell 9% after its Wainua heart drug trial missed its primary goal, raising questions about management credibility.
Comments
Sign in to join the conversation.
No comments yet. Be the first.